Company / SG&A Expense
Beam Therapeutics Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$113.8M
FY2025
5-year range
$57.2M / $116.8M
FY2021-FY2025
Trend
+2.1%
vs FY2024
Sector context
#106 of 213
Health Care
What the data says
At $114M, Beam Therapeutics Inc.'s sg&a expense ranks #108 of 213 in the Health Care sector. Improved from $117M to $114M over the past 2 years.
Based on SEC 10-K filings.
$114M in FY2025 with a 5-year CAGR of +40.8%.
Improved from $117M to $114M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.0%
- 5-Year CAGR
- +40.8%
- 10-Year CAGR
- -
Sector benchmark
#108 of 213 in Health CareTop 50% of 213This company $113.8M Sector average $722.3M
▼
-84.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +40.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 2.1% year-over-year.
- Ranks #106 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $113.8M | +2.1% |
| FY2024 | $111.5M | -4.5% |
| FY2023 | $116.8M | +33.0% |
| FY2022 | $87.8M | +53.4% |
| FY2021 | $57.2M | +178.4% |
| FY2020 | $20.6M | +0.0% |
| FY2019 | $20.6M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026